Envestnet Asset Management
XENE icon

Envestnet Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Envestnet Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Sell
36,005
-63
-0.2% -$3.5K ﹤0.01% 3090
2026
Q1 		$2.1M Buy
36,068
+267
+0.7% +$12.3K ﹤0.01% 2983
2025
Q4 		$1.6M Sell
35,801
-1,647
-4% -$69.2K ﹤0.01% 2996
2025
Q3 		$1.5M Sell
37,448
-1,955
-5% -$68.9K ﹤0.01% 3077
2025
Q2 		$1.23M Sell
39,403
-3,447
-8% -$112K ﹤0.01% 3147
2025
Q1 		$1.44M Sell
42,850
-4,447
-9% -$169K ﹤0.01% 2954
2024
Q4 		$1.85M Sell
47,297
-1,539
-3% -$63.6K ﹤0.01% 2738
2024
Q3 		$1.92M Sell
48,836
-110
-0.2% -$4.43K ﹤0.01% 2683
2024
Q2 		$1.91M Buy
48,946
+769
+2% +$30.7K ﹤0.01% 2624
2024
Q1 		$2.07M Buy
48,177
+2,948
+7% +$136K ﹤0.01% 2549
2023
Q4 		$2.08M Buy
45,229
+1,127
+3% +$39.8K ﹤0.01% 2443
2023
Q3 		$1.51M Buy
44,102
+27,580
+167% +$1.03M ﹤0.01% 2525
2023
Q2 		$636K Buy
+16,522
New +$657K ﹤0.01% 3077

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Envestnet Asset Management's XENE Position: Q2 2026 in Review

Envestnet Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 0.17% in Q2 2026, selling an estimated $3.5K and leaving 36,005 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3090.

Envestnet Asset Management first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. 117 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Envestnet Asset Management held 36,005 shares of Xenon Pharmaceuticals worth $2.17M as of Q2 2026.
  • Envestnet Asset Management sold 63 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.5K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3090 holding.
  • Envestnet Asset Management first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 117 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.